Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Disease
- Diabetes Treatment
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 123563
License Grant
The Licensor granted the Licensee an exclusive, worldwide, royalty-bearing right and license under its patent rights and know-how to develop, manufacture and commercialize sotagliflozin.
License Property
The IP Property is the Licensors diabetes drug candidate sotagliflozin or LX4211, an orally-delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes.
Field of Use
The Licensee will be responsible for all clinical development and commercialization of sotagliflozin for the treatment of type 2 diabetes worldwide and will be solely responsible for the commercialization of sotagliflozin for the treatment of type 1 diabetes outside the United States.
IPSCIO Record ID: 202851
License Grant
The French Licensor grants back an exclusive, worldwide, irrevocable and perpetual license, including the right to sublicense through multiple tiers of sublicense, under the Licensors Technology and interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds outside of the Field.
License Property
Proprietary compounds relating to chronic treatment SERCA activators. Compounds relates to small molecule SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases.
Field of Use
This agreement is for the study of the treatment of type 2 Diabetes, but not on humans.
IPSCIO Record ID: 204371
License Grant
Licensor grants to the French Licensee a non-exclusive, non-sublicensable, license solely to use the materials for the evaluation during the Evaluation Period.
Licensor grants an exclusive, except as to Licensor license, with the right to sublicense solely to Licensees affiliates, under the Research Technology and Licensors interest in Joint Patents, solely to perform the Research Collaboration Plan during the Research Collaboration Term; and on a Selected Compound-by-Selected Compound basis, effective upon Licensees selection of each Selected Compound, an exclusive license, with the right to sublicense through multiple tiers of sublicense, under the Licensed IP Rights and Licensors interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import such Selected Compound and Products containing or comprising such Selected Compound in the Field in the Territory.
License Property
Proprietary compounds relating to chronic treatment SERCA activators. Compounds relates to small molecule SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases.
Field of Use
This agreement is for the study of the treatment of type 2 Diabetes, but not on humans.
IPSCIO Record ID: 209493
License Grant
In consideration of Licensors performance, to date, under the Agreement and its agreement herein to relinquish all of its rights in and to the Licensee Products.
License Property
The rights relate to the sale of Metformin in the United States. Metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight.
Field of Use
This agreement is for the pharmaceutical industry.
Metformin is used in the treatment of diabetes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
